Navigation Links
Carrington Retains Milkie/Ferguson to Explore Financial Alternatives
Date:1/30/2008

IRVING, Texas, Jan. 30 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc. (OTC Bulletin Board: CARN) said it retained Milkie/Ferguson Investments, Inc. as its financial advisor to assist it in exploring a range of financial alternatives.

"Our hiring of a financial advisor is a continuation of our efforts to thoroughly consider our business model and all opportunities going forward," said Carlton Turner, PhD, chief executive officer of Carrington. "We have valuable technologies and assets which we believe have significant emerging potential and we look forward to working with Milkie/Ferguson on these initiatives."

About Carrington

Carrington Laboratories, Inc. is an ISO 9001-certified, research-based, biopharmaceutical and consumer products company currently utilizing naturally-occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care, as well as to manufacture and market the nutraceutical raw material Manapol(R) and cosmetic raw material Hydrapol(TM). Carrington also manufactures and markets consumer products and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. Carrington's DelSite Biotechnologies subsidiary is developing its proprietary GelSite(R) polymer technology designed to provide controlled release of peptide and protein-based drugs. A second technology Gelvac(TM) is designed for dry powder nasal delivery of vaccines without the need for preservatives, adjuvants, cold storage and shipping under cold conditions. One influenza vaccine, (H1N1 antigen) with this technology, has been stable for more than three years at room temperature.

Carrington's technology is protected by more than 130 patents in 26 countries. Select products carry the CE mark, recognized by more than 20 countries around the world. For more information, visit http://www.carringtonla
'/>"/>

SOURCE Carrington Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Carrington Reports Third Quarter 2007 Results
2. Carrington Reports on ISO 9001:2000 Inspection
3. Carrington Laboratories Common Stock Now Trading on the OTC Bulletin Board: CARN.OB
4. Carrington and DaySpring Pharma Extend and Formalize Agreement for Distribution of Diabetic and Radiation Products Into Physician Market
5. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
6. Carrington Reports on ISO 9001:2000 Inspection at Sabila Industrial in Costa Rica
7. Carrington Completes $8 Million Financing
8. Carrington Reports Second Quarter 2007 Results
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Pharma Holdings, Inc. Retains HC International, Inc. to Implement Investor Relations Program
11. Biomoda, Inc. Retains MicroCap Management, LLC as its Lead Corporate Communications and Broker Relations Firm.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)... Nikon Corporation, an innovator of advanced optical instruments, ... agreement with Harvard University granting Nikon the rights ... technology. Under the terms of the agreement, Nikon ... them with the N-STORM name. ,, Nikon ...
(Date:12/3/2009)... Inc. (Nasdaq: PPHM ) today announced that it will ... year 2010 on December 10, 2009 at 7:00 a.m. EST ... the results at 11:30 a.m. EST on the same day. ... second quarter ended October 31, 2009 and will review recent ...
(Date:12/2/2009)... MATK ) announced today that it intends to release ... on December 16, 2009, at approximately 4:00 p.m. Eastern Time ... will conduct a conference call to discuss these results with ... live via webcast by visiting Martek,s web site at ...
(Date:12/2/2009)... Reportlinker.com announces that a new market ... ,, Drug Discovery Technologies - A ... ,, http://www.reportlinker.com/p0164246/Drug-Discovery-Technologies---A-Global-Update-of-Market-Trends--Opportunities.html ,, Drug ... element of every pharmaceutical company,s business strategy. ...
Breaking Biology Technology:Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 2Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 3Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results 2Martek to Announce Fourth Quarter and Fiscal Year 2009 Results 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 8Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 9
... AutoImmune Inc. (OTC,Pink Sheets: AIMM) today reported a net loss ... three months ended June 30, 2008, compared with,a net loss ... for the,three months ended June 30, 2007. For the six ... $0.01 per share basic and diluted, compared,with net loss of ...
... Campbell Alliance, the leading,management consulting firm specializing in ... Naeymi-Rad has been appointed Chief,Operating Officer. His former ... head of the firm,s Brand Management Practice will ... This new senior executive management role for ...
... Campbell Alliance, the leading,management consulting firm specializing ... Darius Naigamwalla has been appointed Senior,Vice President and ... replaces Nader Naeymi-Rad, who was recently promoted to ... has been a member of the Brand Management ...
Other Biology Technology:AutoImmune Inc. Reports 2008 Second Quarter Financial Results 2AutoImmune Inc. Reports 2008 Second Quarter Financial Results 3Nader Naeymi-Rad Appointed Chief Operating Officer at Campbell Alliance 2Nader Naeymi-Rad Appointed Chief Operating Officer at Campbell Alliance 3Darius Naigamwalla Appointed Senior Vice President and Head of the Brand Management Practice at Campbell Alliance 2
(Date:12/3/2009)... co-workers discovered that specific types of human papillomavirus (HPV) ... pathogens cause cells to degenerate. It is known today ... E7. Both proteins switch off different cellular control functions, ... Rsl and his co-workers at DKFZ have now discovered ...
(Date:12/3/2009)... the CTRC-AACR San Antonio Breast Cancer Symposium continues to ... leaders from industry and academia with the goal of ... 8,500 scientists and other professionals will gather at the ... Dec. 9-13, 2009. The symposium is a partnership between ...
(Date:12/3/2009)... design of the upcoming forest deal at Copenhagen in order ... the University of Leeds. , Writing today in ... of the carbon credit payments to be agreed at Copenhagen, ... be made to forest dwellers directly, and their property rights ...
Breaking Biology News(10 mins):Papillomavirus silences innate immune response 2CTRC-AACR San Antonio Breast Cancer Symposium continues to expand 2Forest deal at Copenhagen must avoid creating 'carbon refugees' 2Monsanto Licenses Use of Cellectis Innovative Genome Modification Technology 13776 1Monsanto Licenses Use of Cellectis Innovative Genome Modification Technology 13776 2Monsanto Licenses Use of Cellectis Innovative Genome Modification Technology 13776 3St Lukes Episcopal Hospital First in Houston to Offer Revolutionary Noninvasive Tumor Treatment 55891 1St Lukes Episcopal Hospital First in Houston to Offer Revolutionary Noninvasive Tumor Treatment 55891 2St Lukes Episcopal Hospital First in Houston to Offer Revolutionary Noninvasive Tumor Treatment 55891 3Increasing Health Center Capacity by 20 Million Patients Could Save More Than 24200 Billion Over the Next Decade 55888 1Increasing Health Center Capacity by 20 Million Patients Could Save More Than 24200 Billion Over the Next Decade 55888 2Increasing Health Center Capacity by 20 Million Patients Could Save More Than 24200 Billion Over the Next Decade 55888 3
... popular smoking cessation drug dramatically reduced the amount a ... Medicine study has found.,Heavy-drinking smokers in a laboratory setting ... drug varenicline compared to those taking a placebo, according ... Biological Psychiatry . , The group taking varenicline, sold ...
... their apparent ability to store fat more efficiently than ... has long been suspected that female sex hormones are responsible, ... for the first time drawn a link between one hormone ... childbearing. , On average, women have 6 to 11 percent ...
... origami", the way that proteins fold is vital to ... of Leeds have discovered this is a ,hit and ... before they form the correct structure for their intended ... functions and play a crucial role in the growth, ...
Other Biology News:1 drug may help people both lay down the drink and put out the cigarette 2Why do women store fat differently from men? 2Unfolding 'nature's origami' 2
... a cocktail of 3 siRNAs specifically targeted ... most popular product. The siTrio reagent guarantees ... your target gene when used under standard ... confirmation of optimal transfection with one of ...
... a compact benchtop and stackable multi-function ... with a large display screen to ... Air circulation inside to evenly distribute ... be easily calibrated from the microprocessor ...
... Nonanoyl-N-methylglucamide ... properties. Can be readily removed by ... Purity: ≥98% by HPLC. ... nm): 2 O. CMC 19 ...
...
Biology Products: